The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on products launched in 2021, or in anticipation of new product announcements.
Sage Therapeutics
Sage Therapeutics Inc. (NASDAQ:SAGE) schizophrenia and major depressive disorders. The company reported on the 15th of September that the FDA had granted Fast Track Designation to its drug SAGE-718, paving the way for the company to develop the drug as a potential treatment for Huntington’s disease.
The stock trades at an attractive P/E ratio of 3.73, making it an exciting option for value investors. Moreover, analysts expect Sage’s earnings to grow by more than 185% this year, before rising at an average annual rate of 41% over the next five years.
Technically, Sage Therapeutics shares seem to be trading within an ascending channel formation in the intraday chart. As a result, the stock has advanced to trade above the 100-day moving average.
However, given its exciting valuation, anticipation for new product development and growth prospects, investors could target extended gains at about $46.06, or higher at $49.17, while $40.21 and $36.92 are crucial support zones.
CRISPR Therapeutics AG
CRISPR Therapeutics AG (NASDAQ:CRSP) develops treatments for diseases in the areas of oncology, regenerative medicine, and hemoglobinopathy.
Its partnership with Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) helped propel its meteoric revenue growth in 2021, setting it well for momentum investing in 2022. The stock trades at a reasonable P/E ratio after plunging more than 50% since June.
Technically, CRISPR shares seem to be trading within an
